Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715801 | 0.88 | PIK3CG (0.42) | PIK3CGALDH1A1PTGS2KMT2ANPC1 | |
| SCHEMBL470117 | 0.87 | PIK3CD (0.35) | PIK3CGLMNAMEN1KMT2AMAPT | |
| SCHEMBL470058 | 0.85 | NPC1 (0.33) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL714369 | 0.82 | PIK3CG (0.46) | PIK3CGPTGS2ABL1 | |
| SCHEMBL713695 | 0.82 | KMT2A (0.39) | PIK3CGALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL459435 | 0.82 | SLC9A1 (0.36) | PIK3CGALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL470076 | 0.81 | HTR6 (0.34) | PIK3CGALDH1A1PTGS2LMNAKMT2A | |
| SCHEMBL713738 | 0.81 | RAB9A (0.36) | PIK3CGPTGS2MEN1KMT2ANPC1 | |
| SCHEMBL720604 | 0.81 | HTR6 (0.36) | PIK3CGALDH1A1CYP1A2KMT2ANPC1 | |
| SCHEMBL720605 | 0.81 | HTR6 (0.38) | PIK3CGALDH1A1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2406255-B1 | 4-OXADIAZOL-2-YL-INDAZOLES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2015-04-29 | — | — | EP | disclosed |
| US-8524751-B2 | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases | GlaxoSmithKline Intellecutual Property Development (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524751-B2 | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases | GlaxoSmithKline Intellecutual Property Development (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524751-B2 | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases | GlaxoSmithKline Intellecutual Property Development (GB) | 2013-09-03 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010102958-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CG 2718/4885ALDH1A1 799/4885CYP1A2 1522/4885 |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | CDK3, CDK13, AKT3 | PIK3CG 33/4885ALDH1A1 3950/4885CYP1A2 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.